Table 1 Demographics of a group of patients with NSCLC and poor PS treated with gefitinib 250 mg day−1 in an EAP (Maione, ICE abs; Gridelli et al, 2003). Reproduced with permission.
Patients, n | 41 |
Male : female, n | 26 : 15 |
Median age (range) (years) | 60 (38–69) |
Disease stage, n | |
IIIb | 4 |
IV | 37 |
Eastern Cooperative Oncology Group | |
performance status 2/3, n | 29/12 |
Tumour histology, n | |
Squamous-cell carcinoma | 17 |
Adenocarcinoma | 21 |
Undefined | 3 |
Prior chemotherapy regimens, n | |
0/1/⩾2 | 1/16/24 |
